| Mrs Raeanne L Albertson, MS, CCC-SLP | |
|
2935 East Ave S, La Crosse, WI 54601-7243 | |
| (608) 787-5572 | |
| (608) 787-7775 |
| Full Name | Mrs Raeanne L Albertson |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 2935 East Ave S, La Crosse, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396972196 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 3259-154 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Raeanne L Albertson, MS, CCC-SLP 2935 East Ave S, La Crosse, WI 54601-7243 Ph: (608) 787-5572 | Mrs Raeanne L Albertson, MS, CCC-SLP 2935 East Ave S, La Crosse, WI 54601-7243 Ph: (608) 787-5572 |
News Archive
Few Americans know what a "medical loss ratio" is, but a fierce struggle over how to calculate it under the new health care reform law will determine how much insurers must spend on patient care and how much they can retain for administration and profits. This is but one of many battles that will emerge as federal and state regulators develop regulations to implement reform (5/23).
NanoViricides, Inc. announced today that March 29th, 2012 has been confirmed by the US FDA as the date for its initial meeting with the Company's scientists. This pre-IND meeting will focus on FluCide, designated as NV-INF-1, the Company's novel anti-influenza drug.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that its abstract titled "ACH-1625 Demonstrates Sustained Viral Suppression in Presence of Uncommon Drug Resistant HCV Variants: Pharmacokinetic, Pharmacodynamic and Clinical Virology Analysis of Phase I Study" has been accepted as a late breaking poster presentation at the 61st Annual Meeting of the American Association for the Study of Liver Disease The Liver Meeting 2010 being held October 29-November 2, 2010 in Boston.
A survey of men age 40 to 74 found that 54 percent said that they would still opt for a popular prostate cancer screening test despite recent recommendations that the test not be performed, finds a new study in American Journal of Preventive Medicine. Only 13 percent said they would choose not to be tested.
Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.
› Verified 3 days ago
Aimee A Balistreri, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Stacey L. Burds, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 700 West Ave S, La Crosse, WI 54601 Phone: 608-785-0940 | |
Cynthia G Meisner, Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Ana Carolina Thormann, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Sarah E Graboski, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1900 South Ave, La Crosse, WI 54601 Phone: 920-412-8047 | |
Taryn Jean Simon, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Julie C Wise, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 |